Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine + peginterferon alfa-2a for advanced systemic mastocytosis (KIT exon 17 mutations)
2012-000797-35Phase 2Active
- Sponsor
- Hospital Virgen de la Salud
- Start
- Mar 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine and peginterferon alfa-2a in systemic mastocytosis (SM), sponsored by Hospital Virgen de la Salud. Primary endpoint: Change in bone marrow mast cell infiltration. Started Mar 2013; status: active.
02
Drugs
cladribinepeginterferon alfa-2a
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on 2012-000797-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000797-35.